Dr. Fendler on the Utility of 68Ga-PSMA-11 PET in Prostate Cancer

Video

In Partnership With:

Wolfgang Fendler, MD, discusses the utility of 68Ga-PSMA-11 PET in prostate cancer.

Wolfgang Fendler, MD, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles, discusses the utility of 68Ga-PSMA-11 PET in prostate cancer.

The 68Ga-PSMA-11 PET is a whole-body scan for patients with prostate cancer, explains Fendler. The imaging modality is simple to perform and has been given in the outpatient setting, adds Fendler. Patients receive an intravenous injection of a radionuclide then undergo the whole-body image for about 20 to 30 minutes.

The whole-body image shows where the prostate cancer is located in the body; as such, it can be used as an imaging or staging model at initial diagnosis or biochemical recurrence. In summation, the 68Ga-PSMA-11 PET tool provides insight into tumor location, which can be used to inform further treatment decisions, concludes Fendler.

Related Videos
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine